Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

The CDF: friend and foe?

November 11, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, Cancer, NICE, eric low

Few things in my professional life have troubled me more than the Cancer Drugs Fund (CDF) since its inception in …

Feature
Lucentis image

NICE ‘yes’ to Lucentis – with price cut

October 25, 2013
Sales and Marketing Dillon, Lucentis, NICE, Novartis

A price cut is the deal-breaking condition attached to NICE’s final draft guidance recommending Lucentis as an option for patients …

News
Jetrea image

NICE ‘yes’ for Jetrea

October 23, 2013
Sales and Marketing Jetrea, NHS, NICE, eye

Jetrea has completed its seemingly inexorable journey to NHS use in England and Wales for a rare eye condition following …

News
Eisai image

Eisai: reform NICE or we’ll pull out of the UK

October 21, 2013
Research and Development, Sales and Marketing Eisai, Hatfield, Hunt, NICE

Eisai has criticised NICE for being too narrow minded on assessing new drugs, and has warned it may pull its …

News

Astellas gets NICE nod

October 18, 2013
Sales and Marketing Cancer, NHS, NICE, Xtandi

Astellas Pharma’s new prostate cancer drug Xtandi which has been shown to shrink and kill cancer cells, has been recommended …

News
NHS image

Patients should ‘top up’ NHS costs

October 16, 2013
Sales and Marketing Dixon, England, NHS, NICE, top up

A leading doctor believes that NHS patients must produce top up payments for treatments for non-life threatening conditions. Speaking at …

News
Pixuvri image

Price cut not enough for Pixuvri

October 15, 2013
Sales and Marketing Cell Therapeutics, NICE, pixuvri

NICE is still saying no to Cell Therapeutics’ lymphoma drug Pixuvri, despite the firm offering a discount on the treatment’s …

News

SMC must be ‘more flexible’ – health minister

October 9, 2013
Sales and Marketing CDF, NICE, SMC

The Scottish health secretary Alex Neil has announced a series of fundamental changes to improve access to new medicines in …

News
Andrew Lansley

New UK drug pricing plans ‘delayed’

October 7, 2013
Medical Communications, Sales and Marketing Drug pricing, Hunt, Lansley, NHS, NICE, VBP

News
mabthera image

NICE U-turn on MabThera

October 3, 2013
Sales and Marketing MabThera, NHS, NICE, Roche

NICE is thinking about recommending Roche’s MabThera for a rare autoimmune condition – a move which represents a partial victory …

News

Cancer survival rates linked to government spending in EU

October 1, 2013
Research and Development, Sales and Marketing CDF, Cancer, EU, NICE

The bigger an EU country’s healthcare budget, the greater its cancer patients’ prospects of survival, according to new research released …

News
hunt image

Cancer Drugs Fund to run until 2016

September 30, 2013
Research and Development, Sales and Marketing CDF, Cameron, NHS, NICE, VBP

England’s Cancer Drugs Fund will run until 2016 and be given a £400 million boost under plans announced by the …

News
NICE

NICE recommends ovarian cancer drug Caelyx

September 27, 2013
Sales and Marketing NICE, Yondelis, ovarian cancer

News
NHS image

Cancer Drugs Fund to stay, government to announce

September 27, 2013
Medical Communications, Sales and Marketing CDF, Cameron, NHS, NICE, VBP, prime minister

The UK’s prime minister is set to announce that the controversial Cancer Drugs Fund will remain in place after March …

News
Xalkori image

NICE: final ‘no’ for Xalkori

September 25, 2013
Sales and Marketing NICE, NSCLC, Pfizer, Xalkori

Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026